GE Healthcare Your partner in Atrial Fibrillation detection, treatment and follow-up Atrial Fibrillation is the most common sustained abnormal heart rhythm worldwide with an estimated 6 Million people currently affected in Europe and numbers set to increase.1

GE Healthcare’s portfolio of products can help to identify and monitor those patients even with infrequent A Fib, assist in providing treatment where deemed necessary and support the clinician in the required follow up. Diagnosis – Holter SEER* 1000 Holter recorder, combined with the Holter analysis software CardioDay**, puts the equipment required to diagnose A Fib patients in the hands of those that need it most. The proven algorithms in CardioDay form the basis for comprehensive and fast evaluation of the recorded ECG data. A Fib analysis including frequency measurement give a further insight...

Treatment Option – Ablation Follow-up - CardioLab electrophysiology recording system interfaces with ablation devices which empowers critical thinking by combining clinical performance with advanced documentation, administrative reporting and IT integration. It is designed to help clinicians meet key clinical and administrative challenges. CardioLab. Trusted for more than 20 years. With the legacy of Prucka inside, CardioLab helps deliver: • Excellent signal quality to help visualize small signals and differentiate physio logic signals from noise – even during ablation and pacing • Accurate measurement...

Atrial Fibrillation Atrial fibrillation is the most commonly sustained arrhythmia, affecting up to 2% of the European population1. The incidence of AFib is projected to grow, perhaps even doubling in the next 50 years1. Atrial fibrillation is related to haemodynamic impairment and thromboembolic events which have significant related morbidity, mortality and cost4. Additionally Stroke rate among AFib patients averages 5% per year which is 2 to 7 times higher than in in the normal populations4; around 15% of total stroke cases in the US are attributed to AF (Kim et al., 2011)5. In a study conducted...